<DOC>
	<DOCNO>NCT00877487</DOCNO>
	<brief_summary>The primary objective study evaluate maintenance efficacy , measure Adult ADHD Rating Scale Prompts ( Adult ADHD-RS prompt ) Clinical Global Impression - Severity ( CGI-S ) score , randomize withdrawal design subject ADHD stable treatment commercial SPD489 minimum 6 month maintain screen dose commercial SPD489 .</brief_summary>
	<brief_title>Safety Efficacy Vyvanse Adults With Attention-Deficit/Hyperactivity Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Lisdexamfetamine Dimesylate</mesh_term>
	<criteria>1 . Subject must 1855 year age , inclusive time consent . 2 . Female subject must negative serum beta Human Chorionic Gonadotropin ( HCG ) pregnancy test Screening negative urine pregnancy test baseline agree comply applicable contraceptive requirement protocol . 3 . Subject documented diagnosis ADHD meet DSMIVTR™ adult prompt criteria history primary diagnosis ADHD prior treatment . 4 . Subject Baseline score &lt; 22 use Adult ADHDRS prompt CGIS score ≤3 . 5 . Subject stable treatment commercial SPD489 ( 30 , 50 , 70mg ) minimum least 6 month precede Screening Visit acceptable tolerability.Prior treatment commercial SPD489 6 month precede Screening Visit must document prescription record , prescribe physician note , pharmacy record . Those subject whose primary care physician ( PCP ) someone Principal Investigator ( PI ) require provide documentation site . 6 . Subject must minimum level intellectual functioning , determine Investigator . 7 . Subject willing able comply test requirement define protocol . 8 . Subject able swallow capsule . 9 . Subject must able provide write , personally sign date informed consent participate study , accordance International Conference Harmonisation ( ICH ) Good Clinical Practice ( GCP ) Guideline E627 applicable regulation , complete studyrelated procedure . 1 . Subject current comorbid psychiatric disorder either control medication prohibit study uncontrolled associate significant symptom . Prohibited disorder include associated diagnosis include limited severe comorbid Axis II disorder severe Axis I disorder ( Post Traumatic Stress Disorder [ PTSD ] , psychosis , bipolar illness , pervasive developmental disorder , severe obsessive compulsive disorder , severe depressive severe anxiety disorder ) . Other symptomatic manifestation ( agitated state ) contraindicate treatment SPD489 confound efficacy safety assessment opinion examine physician also prohibit . Comorbid psychiatric diagnosis establish psychiatric evaluation include Structured Clinical Interview DSMIVTR™ disorder ( SCIDI ) . 2 . Subject currently consider suicide risk , previously make suicide attempt prior history , currently demonstrate suicidal ideation . 3 . The subject body mass index ( BMI ) &lt; 18.5 ≥40 . 4 . Subject concurrent chronic acute illness ( severe allergic rhinitis infectious process require antibiotic ) , disability , condition might confound result safety assessment administer study might increase risk subject . Similarly , subject exclude additional condition ( ) Investigator 's opinion would prohibit subject completing study would best interest subject . This would include significant illness unstable medical condition could lead difficulty comply protocol . Mild , stable asthma exclusionary . 5 . Subject history seizure ( infantile febrile seizure ) , tic disorder , current diagnosis and/or know family history Tourette 's Disorder . 6 . Subject known history symptomatic cardiovascular disease , advanced arteriosclerosis , structural cardiac abnormality , cardiomyopathy , serious heart rhythm abnormality , coronary artery disease , transient ischemic attack stroke serious cardiac problem may place increased vulnerability sympathomimetic effect stimulant drug . 7 . Subject know family history sudden cardiac death ventricular arrhythmia . 8 . Subject clinically significant ECG clinically significant laboratory abnormality Screening . 9 . Subject current abnormal thyroid function , define abnormal Screening thyroid stimulate hormone ( TSH ) thyroxine ( T4 ) . Treatment stable dose thyroid medication least 3 month permit . 10 . Subject history moderate severe hypertension rest sit systolic blood pressure &gt; 139mmHg diastolic blood pressure &gt; 89mmHg . Subjects wellcontrolled mild moderate hypertension single antihypertensive agent allow . 11 . Subject take medication exclude ( Please refer Table 2 ) . 12 . Subject document allergy , hypersensitivity , intolerance amphetamine . 13 . Subject recent history ( within past 6 month ) suspect substance abuse dependence disorder ( exclude nicotine ) accordance DSMIVTR™ criterion . 14 . Subject positive urine drug result Screening ( exception subject 's current stimulant therapy ) . 15 . Subject take investigational compound central nervous system ( CNS ) effect take part clinical trial ADHD 6 month prior Screening Visit . 16 . Subject take part investigational trial within 30 day prior Screening Visit . 17 . Subject glaucoma . 18 . Subject take medication CNS effect affect performance , chronic use sedate antihistamine decongestant sympathomimetics ( 7 day prior Screening ) . Stable use bronchodilator inhaler exclusionary . 19 . Subject female pregnant lactating . 20 . Subjects previously enrol study subsequently withdraw . 21 . Subject well control SPD489 acceptable tolerability ( Adult ADHDRS prompt score ≥22 ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>ADHD</keyword>
</DOC>